Lateral Flow Assay Market Projected to Hit $16.37B by 2031, Driven by Multiplex and CRISPR Innovations

  • The global lateral flow assay market is projected to grow from $11.04B in 2026 to $16.37B by 2031, at a CAGR of 8.2%.
  • Multiplex detection assays and CRISPR-enhanced nucleic acid testing are driving innovation in the sector.
  • North America leads the market, while Asia-Pacific is the fastest-growing region.
  • Key players include Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Becton, Dickinson and Company.

The lateral flow assay market is evolving beyond single-analyte tests to multiplex and CRISPR-enhanced formats, addressing clinical demand for rapid, decentralized diagnostics. The shift is supported by continued home testing adoption and manufacturing scale agreements, positioning the sector for sustained growth despite regulatory and accuracy perception challenges.

Technological Advancements
How CRISPR-enhanced nucleic acid testing and AI-enabled digital readers will affect the market's sensitivity and specificity.
Regulatory Clarity
Whether the shift from pandemic-era emergency use authorizations to standard licensing procedures will create uncertainty for manufacturers.
Market Expansion
The pace at which Asia-Pacific will grow as a key market, driven by rising investment in medical infrastructure and expanding diagnostic access.